ACCURAY INC
No enriched coverage for $ARAY in the last 7 days.
No SEC Form 4 filings for $ARAY in the last 30 days.
Accuray Incorporated (NASDAQ:ARAY) insiders lost US$95k on their investments after a 17% stock drop, despite purchasing US$216.4k worth of stock at an average of US$0.68 over the past year. Director Steven Mayer recently bought US$135k worth of shares, indicating continued confidence, though overall insider ownership is relatively low at 4.8%. The company's recent losses warrant caution for potential investors.
Accuray Incorporated has announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will lead the company's global commercial organization, focusing on transformation, strengthening execution, and enhancing commercial performance. His extensive experience in medical technology, including a commercial turnaround at Johnson & Johnson MedTech, is expected to drive Accuray's long-term value creation and growth in systems and services sales.
This page provides a comprehensive resource for Accuray Incorporated (ARAY) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights how these documents provide insights into the company's financial performance, governance, and key corporate events, with AI-powered summaries to help users quickly grasp the significance of each filing. Recent filings cover topics such as director ownership, quarterly financial results, executive compensation, and equity grants.
